Marshall Wace’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Marshall Wace’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-123,039	Closed	-$73K	–	3991
2022 Q2	$73K	Sell	123,039 -98,444	-44%	-$94.3K	﹤0.01%	3304
2022 Q1	$292K	Sell	221,483 -140,687	-39%	-$228K	﹤0.01%	2976
2021 Q4	$945K	Buy	362,170 +143,293	+65%	+$433K	﹤0.01%	2499
2021 Q3	$681K	Buy	+218,877	New	+$730K	﹤0.01%	2238

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PTP

Platform Technology Partners New York $519M AUM 20% 1-Year Est. Return

Marshall Wace's PHAS Position: Q3 2022 in Review

Marshall Wace sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2022, closing a stake of 123,039 shares — an estimated $73K sold.

Marshall Wace first reported a position in PHAS in Q3 2021 and held it in 4 quarters. The position peaked at $945K in Q4 2021. 38 funds tracked by Wall St. Rank hold PHAS as of Q3 2022.

Marshall Wace reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Marshall Wace sold 123,039 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $73K.
Marshall Wace first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
Marshall Wace's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $945K in Q4 2021.
38 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Marshall Wace's 13F filing for Q3 2022, filed 14 Nov 2022.